Adipose tissue, also known as body fat, is more than just a storage of excess calories. It is a complex and dynamic organ that plays a vital role in regulating metabolism, inflammation, immunity, and skin health. However, adipose tissue can also be a source of various diseases, such as obesity, diabetes, cardiovascular disorders, and cancer. Therefore, understanding the biology and function of adipose tissue is crucial for developing new and effective treatments for these conditions.
One of the leading companies in the field of adipose tissue research is Exsymol, a Monaco-based manufacturer of active ingredients for the cosmetics and nutrition sectors. Exsymol has recently announced an unprecedented collaboration with ExAdEx-Innov, a French biotechnology startup from Nice University, focused on research applied to human adipose tissue1.
ExAdEx-Innov has developed a patented technology that allows for the generation of ex vivo research models of human adipose tissue. These models are clinically relevant and incorporate the complexity of 3D biology of native adipose tissue. They are derived from adipose stem cells that are stimulated to proliferate and differentiate on a bioactive support made of the native tissue matrix. These models have unique characteristics, such as long-term viability, a complete extracellular matrix structure, lipid droplet size comparable to endogenous tissue, and the ability to respond to various stimuli2.
The ExAdEx technology offers a unique opportunity for innovation in research and product development in the field of adipose tissue. Working in partnership with Exsymol opens up new possibilities in the beauty industry. Exsymol recognizes the innovation opportunities of the patented technology developed by ExAdEx-Innov, which allows for the generation of ex vivo research models of human adipose tissue. These unique models are clinically relevant and incorporate the complexity of 3D biology of native adipose tissue. This collaboration marks a significant step in the repositioning and development of cosmetic assets, using high-quality ex vivo human adipose tissue models that closely resemble in vivo tissue to assess new claims and generate relevant data1.
According to Dr. Daniel Auriol, the founder and CEO of ExAdEx-Innov, the collaboration with Exsymol is a win-win situation for both parties. “Exsymol brings its expertise and know-how in the design and production of active ingredients for the cosmetics and nutrition sectors, while ExAdEx-Innov provides its innovative technology and scientific support for the evaluation of these ingredients on human adipose tissue models,” he says3.
The collaboration between Exsymol and ExAdEx-Innov is expected to result in the development of new and improved active ingredients that target adipose tissue and its related functions, such as skin firmness, elasticity, hydration, and inflammation. These ingredients will be based on natural and sustainable sources, such as plant extracts, marine algae, and peptides. They will also be compatible with the current trends and demands of the beauty market, such as clean, vegan, and cruelty-free products3.
The beauty industry is constantly evolving and looking for new ways to enhance the health and appearance of the skin. By partnering with ExAdEx-Innov, Exsymol is demonstrating its commitment to innovation and sustainability, as well as its vision for the future of beauty. By exploring new research prospects on adipose tissue, Exsymol is aiming to create products that are not only effective, but also respectful of the environment and the consumers.
